Novo Nordisk and Roche Diabetes Care have launched NovoRapid PumpCart, the first prefilled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps. This new treatment solution, which contains Novo Nordisk’s rapid-acting insulin NovoRapid (insulin aspart) is expected to make insulin pump therapy… Read more
JDRF announced that JDRF-funded partner, ViaCyte, Inc. has for the first time ever implanted a person with type 1 diabetes with an experimental encapsulated cell therapy product candidate, called VC-01, which is being developed for the treatment of type 1 diabetes. This individual, and others to follow, is participating in a trial to evaluate the safety and efficacy of the VC-01 product candidate, a potential replacement source of insulin-producing cells. Read more
The FDA has approved Dexcom’s CGM remote mobile communications device: Dexcom SHARE. Dexcom SHARE, an accessory to the Dexcom G4 PLATINUM Continuous Glucose Monitoring System, uses a secure wireless connection to transmit the glucose levels of a person with diabetes to the smartphones Read more
Medtronic has begun enrolling patients in an investigational device exemption (IDE) study of its new and innovative Predictive Low Glucose Management (PLGM) technology. The start of this study marks a critical step toward development of an artificial pancreas in the U.S. market. Read more
On October 24-25th, 2014, hundreds of women with diabetes and their loved ones will descend upon the Embassy Suites LAX North for DiabetesSisters’ power-packed weekend conference. This will be the eighth Conference hosted by DiabetesSisters and the first time it will convene in the Los Angeles, CA area. Read more
On Thursday the United States Food and Drug Administration approved Trulicity, by Eli Lilly and Company, a once weekly, injectable GLP-1 treatment for adults with Type 2 diabetes.
Novo Nordisk has been granted marketing authorization by the European Commission for a new injectable, Xultophy, for the treatment of Type 2 diabetes in adults.
Xultophy is the brand name for IDegLira, the first once-daily single injection combination of insulin degludec (Tresiba) and liraglutide (Victoza). Read more
Data presented today at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen for type 2 diabetes patients.
Ryzodeg is a combination of two distinct insulin analogues , insulin degludec (Tresiba) and insulin aspart (Novolog) in the ratio of 70% and 30%, making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes. Read more
JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, and Tidepool, a Silicon Valley-based non-profit organization committed to reducing the burden of T1D, announced a partnership supported by JDRF funding for data access technology for people with T1D who use insulin pumps and continuous glucose monitors (CGMs) through a device agnostic cloud platform. Read more
Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The study investigates once-daily Tresiba (insulin degludec) versus basal insulin Levemir (detemir), both in combination with bolus insulin Novolog (aspart) in a 52-week trial in children and adolescents with type 1 diabetes. This trial is the first to look into the long-term safety of Tresiba in children and adolescents (from age 1 to less than 18 years) and the results show that Tresiba in combination with Novolog (Novorapid) effectively improved long-term glycemic control.